Compare TG Therapeutics Inc (TGTX) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Valero Energy Corporation — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.53B), while Valero Energy Corporation trades at $389.25 (market cap $110.23B). The key difference: Valero Energy Corporation is far larger — about 12.9× TG Therapeutics Inc's market cap, and Valero Energy Corporation pays a 1.25% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | VLO | |
|---|---|---|
Market Cap | $8.53B | $110.23B |
Sector | Health | Energy |
52-Week High | $59.06 | $388.95 |
52-Week Low | $26.94 | $156.39 |
Enterprise Value | $8.74B | $113.71B |
Dividend Yield | — | 1.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Valero Energy (VLO) trades at $382.85, up 3.27% today, reflecting strong momentum amid favorable refining conditions. The stock exhibits a bullish technical trend, with recent earnings beats and a Zacks Rank #1 (Strong Buy) as of September 9, 2026. Fundamentals show robust profitability with a 29.31% ROE, though revenue has declined from $176.4B in 2022 to $122.7B in 2025. Analyst consensus is bullish with a $345.55 price target, and the company maintains a solid balance sheet with $4.66B in cash.
VLO's outlook is supported by tight fuel supplies and healthy demand, with projected 2026 net income of $7.2B. Key risks include volatile energy prices and potential regulatory pressures. The stock offers growth potential but faces headwinds from revenue declines and geopolitical factors affecting the energy sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
